Home » Stocks » PDL BioPharma

PDL BioPharma, Inc. (PDLI)

Stock Price: $3.16 USD -0.35 (-9.97%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 360.07M
Revenue (ttm) 85.10M
Net Income (ttm) -108.81M
Shares Out 113.95M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE 64.94
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $3.16
Previous Close $3.51
Change ($) -0.35
Change (%) -9.97%
Day's Open 3.15
Day's Range 3.05 - 3.18
Day's Volume 1,240,283
52-Week Range 1.71 - 3.52

More Stats

Market Cap 360.07M
Enterprise Value 195.28M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 113.95M
Float 104.26M
EPS (basic) -0.92
EPS (diluted) -0.93
FCF / Share 0.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 2.27%
Payout Ratio n/a
Shares Short 11.13M
Short Ratio 9.73
Short % of Float 11.11%
Beta 0.88
PE Ratio n/a
Forward PE 64.94
P/FCF Ratio 44.12
PS Ratio 4.23
PB Ratio 0.69
Revenue 85.10M
Operating Income -142.16M
Net Income -108.81M
Free Cash Flow 8.16M
Net Cash 164.79M
Net Cash / Share 1.45
Gross Margin 15.78%
Operating Margin -167.05%
Profit Margin -498.30%
FCF Margin 9.59%
ROA -3.19%
ROE -15.08%
ROIC -21.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$3.00*
Low
3.00
Current: $3.16
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue54.76198320244590581456381362345
Revenue Growth-72.36%-38.1%31.01%-58.62%1.59%27.39%19.79%5.2%4.95%-
Gross Profit1.14150290240590581456381362345
Operating Income-99.81-50.59194129550546427355344211
Net Income-70.41-68.8611163.6133332226521219991.87
Shares Outstanding119146155164163158140140140127
Earnings Per Share-0.59-0.470.710.392.031.861.661.451.150.54
EPS Growth--82.05%-80.79%9.14%12.05%14.48%26.09%112.96%-
Dividend Per Share---0.100.600.600.600.600.601.00
Dividend Growth----83.33%0%0%0%0%-40%-
Operating Cash Flow-32.44-13.4340.62102301292270213170184
Capital Expenditures76.8153.4510613.06-71.6021.31-241-0.05--
Free Cash Flow44.3740.0214711523031428.43212170184
Cash & Equivalents222458586353279351101176211246
Total Debt27.25125243232254452395310410515
Net Cash / Debt19433334212124.92-100-295-134-199-268
Assets7179641,2431,2151,012962544280269317
Liabilities124234397460316502430348474641
Book Value593730846751696460113-68.12-204-324
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PDL BioPharma, Inc.
Country United States
Employees 109
CEO Dominique P. Monnet

Stock Information

Ticker Symbol PDLI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PDLI
IPO Date January 28, 1992

Description

PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally. The company operates through Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets segments. The Medical Devices segment offers LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Strategic Positions segment develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.